New hemophilia drug hympavzi under safety watch
NCT ID NCT07161687
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks the safety of Hympavzi (marstacimab) in 50 people with hemophilia A or B who do not have inhibitors. Participants receive weekly injections to help control bleeding. The main goal is to monitor any side effects in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Marstacimab (Hympavzi)
What this could lead to
If successful, this could confirm that Hympavzi is a safe, convenient option to prevent bleeding episodes in people with hemophilia A or B.
What could go wrong
This is a small, observational safety study with only 50 participants. It is not designed to prove effectiveness, and rare side effects may not be detected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A OR B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan